Kringle Pharma, Inc. develops and distributes biotechnology products. The Company produces regenerative medicines, cancer therapy medicines, and other products. Kringle Pharma markets its products throughout Japan.

Analyst Report Released By Shared Research Inc.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kringle Pharma Inc (4884 JP)

Analyst Report Released By Shared Research Inc.

[Delayed] Financial Results For The Nine Months Ended June 30, 2024 [Japanese Gaap] (Non-Consolidated)

Analyst Report Released By Shared Research Inc.

Presentation At The 2nd Annual Spinal Cord Injury Investor Symposium

[Delayed] Financial Results For The Six Months Ended March 31, 2024 [Japanese Gaap] (Non-Consolidated)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)